Navigation Links
New Guidelines For Assessing Lymphoma Treatment

An international team of cancer specialists and imaging experts has developed standardized guidelines for assessing lymphoma response to treatment//. The guidelines will provide clinicians worldwide with uniform criteria to compare and interpret clinical trials of lymphoma treatments and should facilitate the development of new therapies.

The new guidelines developed by the International Harmonization Project (IHP) build on criteria for treatment response assessment of non-Hodgkin's lymphoma published in 1999 by an international working group (IWG) of clinicians, radiologists and pathologists. Although the IWG criteria have been widely adopted by clinicians and regulatory agencies and used to approve several treatments, recent advances, including increased use of positron emission tomography (PET) scans and immunohistochemistry in lymphoma response assessment, prompted the IHP to substantially revise the criteria.

The IHP recommendations aim to standardize the parameters used in clinical trials for lymphoma and incorporate the new technologies. In addition, the revised guidelines cover all lymphomas. The recommendations appear in the Jan. 22 online issue of the Journal of Clinical Oncology. Bruce Cheson, M.D., professor of medicine at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital, is senior author of the paper and led the IHP effort.

Integration of PET represents a major change in the guidelines. Malik Juweid, M.D., associate professor of radiology at the UI Roy J. and Lucille A. Carver College of Medicine and a member of the UI Holden Comprehensive Cancer Center, was co-chair of the IHP committee that developed the recommendations for performing and interpreting PET scans in response assessment of lymphoma. The imaging committee, which included world-renowned PET imaging experts from the United States, Europe and Australia, was co-chaired by Sigrid Stroobants from University Hospital Gasthuisberg in Le uven, Belgium.

"This is the first time that standardized guidelines have been recommended on an international level," Juweid said. "These revised criteria for response assessment of lymphoma are unique in that they are the first for any cancer type to formally integrate functional imaging with PET into the more conventional response assessment using clinical, laboratory and radiological measures."

Juweid is a co-author and principal imaging author of the paper outlining the IHP recommendations. He also is senior author of a second paper in the Jan. 22 online issue of the Journal of Clinical Oncology, which details the integration of PET into lymphoma response assessment.

PET is a non-invasive imaging technique that uses radioactivity emitted from injected tracer chemicals to measure and image biological activity. The most commonly used PET radiotracer is fluorodeoxyglucose (FDG), a radiolabeled form of glucose, which is consumed more avidly by tumors than by normal tissue.

In contrast to conventional computed tomography (CT) or magnetic resonance imaging (MRI), PET is able to distinguish between viable tumor and non-cancerous scar tissue that is often left behind after successful treatment of lymphoma. Incorporation of PET imaging into response assessment means that doctors can more accurately determine the nature of any residual mass and essentially rule out persistent cancer within the mass if the scan is PET-negative. This approach will allow researchers to accurately assess how well anti-lymphoma drugs work even when there is a residual mass at the tumor site following treatment.

Adoption of the revised guidelines is expected to have major implications for patient management, says Juweid.

"Many patients with either diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of lymphoma, or Hodgkin's disease, who were previously considered in partial response to treatment based o n the conventional assessment, will now be considered in complete response if their PET scan is negative. Such patients can be safely observed and are expected to have an excellent outcome," Juweid said.

In contrast, Juweid added, the smaller fraction of such patients who are PET-positive after treatment should undergo a biopsy to evaluate the PET-positive lesion unless there already is other compelling clinical and/or biochemical suspicion of persistent disease. If the biopsy is positive, these patients can rapidly be considered for salvage therapy.

The revised guidelines cover the use of PET for assessing all types of lymphoma. For two potentially curable types of lymphoma, DLBCL and Hodgkin's disease, the guidelines recommend that PET always be used to assess post-treatment response. PET also is strongly recommended prior to treatment to determine extent of disease for these lymphomas.

For the other 30 or so other subtypes of lymphoma, most of which are less common, the guidelines offer recommendations for when PET is useful and when it is not, and if PET is used in those cases, what criteria should be fulfilled.

The guidelines also address when a scan should be performed and recommend that PET obtained for response assessment at therapy conclusion be done preferably six to eight weeks after completion of chemotherapy and eight to twelve weeks after radiation. Timing is important because inflammation, which is present in the early weeks following treatment of the tumor, can cause false positive PET scans.

Juweid added that adherence to the guidelines could improve medical practice by minimizing inappropriate practice variation, which should improve patient care.

Source-Newswise
'"/>




Related medicine news :

1. New CPR Guidelines issued by Heart Association
2. New Guidelines Found To Benefit Cardiovascular Treatment
3. Healthy Feeding Guidelines for Children Ages 0 to 24 Months Issued
4. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
5. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
6. FDA To Set New Guidelines To Revise Drug Companies Marketing Tactics
7. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
8. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
9. Guidelines for treatment of juvenile idiopathic arthritis formulated
10. Guidelines For Better Management Of Obsessive-Compulsive Disorder
11. Poultry Workers To Adopt Anti-Flu Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology: